LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 255

Search options

  1. Book: Multiple sclerosis and demyelinating diseases

    Freedman, Mark S.

    (Advances in neurology ; 98)

    2006  

    Author's details ed. Mark S. Freeman
    Series title Advances in neurology ; 98
    Collection
    Keywords Multiple Sclerosis ; Demyelinating Diseases ; Multiple sclerosis ; Demyelination
    Subject code 616.834
    Language English
    Size XVI, 375 S. : Ill., graph. Darst.
    Publisher Lippincott Williams & Wilkins
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT014532549
    ISBN 0-7817-5170-5 ; 978-0-7817-5170-4
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Se 198 -98- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Online: Multiple sclerosis and demyelinating diseases

    Freedman, Mark S.

    (Advances in neurology : v. 98 ; v. 98)

    2006  

    Author's details editor, Mark S. Freedman
    Series title Advances in neurology : v. 98 ; v. 98
    Keywords Multiple sclerosis ; Demyelinating diseases
    Language English
    Size 1 Online-Ressource (xvi, 375 Seiten), Illustrationen
    Publisher Lippincott Williams & Wilkins
    Publishing place Philadelphia
    Document type Book ; Online
    Note Includes bibliographical references and index
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 978-0-7817-5170-4 ; 0-7817-5170-5
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.

    Uccelli, Antonio / Freedman, Mark S

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2022  Volume 28, Issue 9, Page(s) 1326–1328

    MeSH term(s) Humans ; Mesenchymal Stem Cell Transplantation ; Multiple Sclerosis/surgery
    Language English
    Publishing date 2022-07-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585221095427
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.

    Bose, Gauruv / Freedman, Mark S

    Journal of the neurological sciences

    2021  Volume 421, Page(s) 117324

    Abstract: The judicious use of autologous hematopoietic stem cell transplantation (AHSCT) for MS requires understanding the potential benefits, identifying the most appropriate patient, and acknowledging the risks and differences between different protocols. ... ...

    Abstract The judicious use of autologous hematopoietic stem cell transplantation (AHSCT) for MS requires understanding the potential benefits, identifying the most appropriate patient, and acknowledging the risks and differences between different protocols. Recently, AHSCT for MS is occurring more frequently, with a better safety profile than earlier studies. This review assesses recently published studies to determine the advances that have been made and remaining questions that future studies are poised to answer. We included studies from January 2016 to November 2020 with 20 or more patients. The benefits of AHSCT, including "no evidence of disease activity", functional and patient-reported outcomes, novel biomarkers such as brain atrophy or neurofilament light chain, and cost-effectiveness were assessed. The patient selection, treatment protocols, and safety outcomes differ between reports. The overall efficacy of AHSCT is better than standard treatments. Younger patients with highly active disease have greater chance for improvement, while patients who have comorbidities, failed more treatments, and are transitioning to a more progressive phase may not respond as well to AHSCT. The safety profiles for all AHSCT protocols is improving, however the durability of treatment response may not be the same for all protocols. The goal of AHSCT is to stop disease activity, avoid worsening disability, and obviate the need for further disease-modifying treatment, while improving patient quality of life and minimizing treatment-related risk. Results from currently enrolling randomized controlled trials, as well as ongoing registries, will provide more evidence for the safe and appropriate use of AHSCT.
    MeSH term(s) Cost-Benefit Analysis ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Sclerosis/therapy ; Quality of Life ; Transplantation, Autologous
    Language English
    Publishing date 2021-01-18
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2021.117324
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 308: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.

    Coyle, Patricia K / Freedman, Mark S / Cohen, Bruce A / Cree, Bruce A C / Markowitz, Clyde E

    Annals of clinical and translational neurology

    2024  Volume 11, Issue 4, Page(s) 842–855

    Abstract: Four sphingosine 1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these ... ...

    Abstract Four sphingosine 1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head-to-head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real-world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents.
    MeSH term(s) United States ; Humans ; Multiple Sclerosis/drug therapy ; Sphingosine 1 Phosphate Receptor Modulators/adverse effects ; Sphingosine-1-Phosphate Receptors/therapeutic use ; Fingolimod Hydrochloride/adverse effects ; Administration, Oral
    Chemical Substances Sphingosine 1 Phosphate Receptor Modulators ; Sphingosine-1-Phosphate Receptors ; Fingolimod Hydrochloride (G926EC510T)
    Language English
    Publishing date 2024-02-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2740696-9
    ISSN 2328-9503 ; 2328-9503
    ISSN (online) 2328-9503
    ISSN 2328-9503
    DOI 10.1002/acn3.52017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: From progression to progress: The future of multiple sclerosis.

    Oh, Jiwon / Giacomini, Paul S / Yong, V Wee / Costello, Fiona / Blanchette, François / Freedman, Mark S

    Journal of central nervous system disease

    2024  Volume 16, Page(s) 11795735241249693

    Abstract: Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of MS phenotypes according to disease activity and progression, for example, does not adequately ... ...

    Abstract Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of MS phenotypes according to disease activity and progression, for example, does not adequately reflect the underlying pathophysiological mechanisms that may be acting in an individual with MS at different time points. Thus, there is a need for clinicians to transition to a management approach based on the underlying pathophysiological mechanisms that drive disability in MS. A Canadian expert panel convened in January 2023 to discuss priorities for clinical discovery and scientific exploration that would help advance the field. Five key areas of focus included: identifying a mechanism-based disease classification system; developing biomarkers (imaging, fluid, digital) to identify pathologic processes; implementing a data-driven approach to integrate genetic/environmental risk factors, clinical findings, imaging and biomarker data, and patient-reported outcomes to better characterize the many factors associated with disability progression; utilizing precision-based treatment strategies to target different disease processes; and potentially preventing disease through Epstein-Barr virus (EBV) vaccination, counselling about environmental risk factors (e.g. obesity, exercise, vitamin D/sun exposure, smoking) and other measures. Many of the tools needed to meet these needs are currently available. Further work is required to validate emerging biomarkers and tailor treatment strategies to the needs of individual patients. The hope is that a more complete view of the individual's pathobiology will enable clinicians to usher in an era of truly personalized medicine, in which more informed treatment decisions throughout the disease course achieve better long-term outcomes.
    Language English
    Publishing date 2024-05-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2586873-1
    ISSN 1179-5735
    ISSN 1179-5735
    DOI 10.1177/11795735241249693
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.

    Freedman, Mark S

    Neurology. Clinical practice

    2017  Volume 1, Issue 1, Page(s) 66–68

    Language English
    Publishing date 2017-06-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0b013e31823cc2c2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.

    Bose, Gauruv / Freedman, Mark S

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2020  Volume 26, Issue 5, Page(s) 540–547

    Abstract: Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS), affecting patients of all ages, causing neurologic disability if inadequately treated. Some patients have a relatively benign disease course without ... ...

    Abstract Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS), affecting patients of all ages, causing neurologic disability if inadequately treated. Some patients have a relatively benign disease course without significant disability after decades, while a more aggressive course ensues in others and disability progression occurs after only several years. Certain risk factors confer a higher chance of a patient having aggressive MS. Currently over 15 disease-modifying treatments (DMTs) are approved for MS with different efficacy and safety profiles. Deciding which DMT to use in a specific patient requires a careful analysis of a patient's disease course for high-risk factors for early progression, consideration of the efficacy and safety profile for potential therapy, as well as understanding of a patient's lifestyle and expectations. The integration of these factors is the art of precision medicine, a necessary practice in the treatment of patients with MS.
    MeSH term(s) Humans ; Immunologic Factors/administration & dosage ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/drug therapy ; Patient-Centered Care/methods ; Patient-Centered Care/standards ; Precision Medicine/methods ; Precision Medicine/standards
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2020-01-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/1352458519887324
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Multiple sclerosis: Is there a safe time to discontinue therapy in MS?

    Freedman, Mark S

    Nature reviews. Neurology

    2016  Volume 13, Issue 1, Page(s) 10–11

    MeSH term(s) Adult ; Humans ; Immunologic Factors/administration & dosage ; Medication Adherence ; Middle Aged ; Multiple Sclerosis, Chronic Progressive/diagnostic imaging ; Multiple Sclerosis, Chronic Progressive/drug therapy ; Multiple Sclerosis, Chronic Progressive/physiopathology ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/physiopathology
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2016--28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2491514-2
    ISSN 1759-4766 ; 1759-4758
    ISSN (online) 1759-4766
    ISSN 1759-4758
    DOI 10.1038/nrneurol.2016.192
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6257: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 88: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Are we in need of NEDA?

    Freedman, Mark S

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2016  Volume 22, Issue 1, Page(s) 5–6

    MeSH term(s) Disease Progression ; Humans ; Multiple Sclerosis/therapy ; Outcome Assessment (Health Care)/standards
    Language English
    Publishing date 2016-01
    Publishing country England
    Document type Editorial
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/1352458515617249
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top